Successful Treatment of Pure Red Cell Aplasia in Systemic Lupus Erythematosus With a Combination of Rituximab and Mycophenolate Mofetil

Key Points

• Successful treatment involved a combination of rituximab and mycophenolate mofetil, addressing pure red cell aplasia.
• The therapy appears to improve hematological outcomes in individuals with systemic lupus erythematosus.
• Analysis of clinical cases revealed that patients exhibited marked improvement following the treatment regimen.
• This finding may signal a new direction for combination therapies in autoimmune conditions like lupus.